ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $731,518 | +174.7% | 5,808 | +104.2% | 0.00% | +100.0% |
| Q3 2023 | $266,312 | +76.6% | 2,844 | +130.3% | 0.00% | – |
| Q4 2022 | $150,831 | -91.6% | 1,235 | -92.9% | 0.00% | -100.0% |
| Q3 2022 | $1,793,000 | +219.0% | 17,365 | +187.3% | 0.00% | +300.0% |
| Q2 2022 | $562,000 | +56100.0% | 6,044 | +54845.5% | 0.00% | – |
| Q2 2021 | $1,000 | -96.7% | 11 | -95.2% | 0.00% | – |
| Q1 2021 | $30,000 | -80.9% | 231 | -75.5% | 0.00% | – |
| Q4 2020 | $157,000 | +145.3% | 941 | +65.4% | 0.00% | -100.0% |
| Q1 2020 | $64,000 | -74.3% | 569 | -68.2% | 0.00% | -50.0% |
| Q4 2019 | $249,000 | +111.0% | 1,788 | +46.2% | 0.00% | +100.0% |
| Q3 2019 | $118,000 | -81.8% | 1,223 | -78.2% | 0.00% | -83.3% |
| Q2 2019 | $647,000 | +670.2% | 5,615 | +317.5% | 0.01% | +500.0% |
| Q4 2018 | $84,000 | +1100.0% | 1,345 | +1272.4% | 0.00% | – |
| Q2 2018 | $7,000 | – | 98 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Q Global Advisors, LLC | 219,459 | $29,930 | 21.23% |
| RA Capital Management | 10,108,400 | $1,378,583,592 | 18.23% |
| Tri Locum Partners LP | 227,762 | $31,062,182 | 7.85% |
| Vestal Point Capital, LP | 750,000 | $102,285,000 | 7.63% |
| Avoro Capital Advisors LLC | 4,196,661 | $572,340,627 | 7.62% |
| Finepoint Capital LP | 189,272 | $25,812,915 | 7.33% |
| Spyglass Capital Management LLC | 662,888 | $90,404,665 | 6.62% |
| Saturn V Capital Management LP | 113,224 | $15,441,489 | 5.84% |
| Sofinnova Investments, Inc. | 734,284 | $100,141,652 | 5.20% |
| First Turn Management, LLC | 186,581 | $25,445,917 | 4.14% |